Ihmor necrosis factor-a inhibitors and cardiovascular risk in rheumatoid arthritis

Abstract

The use of tumor necrosis factor-α (TNF-α) inhibitors that selectively block important components of the immunopathogenesis of rheumatoid arthritis (RA) is a highly effective and relatively safe treatment for rheumatoid inflammation and can be considered as a new area in the therapy of autoimmune diseases, the basis of which is T- and B-cell immunity suppression. At the same time, it is necessary to conduct prospective studies that will be able to more exactly define the implication of TNF-α in the development of cardiovascular catastrophes and its inhibition in the prevention of cardiovascular events in patients with RA.

Keywords

• ревматоидный артрит
• сердечно-сосудистые осложнения
• фактор некроза опухоли а
• ингибиторы фактора некроза опухоли α